{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:36:44Z","timestamp":1773761804598,"version":"3.50.1"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T00:00:00Z","timestamp":1390867200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0086584","type":"journal-article","created":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T21:31:35Z","timestamp":1390944695000},"page":"e86584","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["Effectiveness and Cost Effectiveness of Oral Pre-Exposure Prophylaxis in a Portfolio of Prevention Programs for Injection Drug Users in Mixed HIV Epidemics"],"prefix":"10.1371","volume":"9","author":[{"given":"Sabina S.","family":"Alistar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas K.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret L.","family":"Brandeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,1,28]]},"reference":[{"key":"ref1","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS) (2012) UNAIDS Report on the Global AIDS Epidemic 2012. Geneva, Switzerland: World Health Organization."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"RM Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"MC Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"ref5","unstructured":"Marrazzo J, Ramjee G, Nair G, <etal>et al<\/etal>.. (2013) Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir\/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003) [Abstract]. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"L Van Damme","year":"2012","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection among people who inject drugs in Bangkok, Thailand: a randomized, double-blind, placebo-controlled trial","volume":"381","author":"K Choopanya","year":"2013","journal-title":"Lancet"},{"key":"ref8","first-page":"463","article-title":"Interim guidance for preexposure prophylaxis for the prevention of HIV infection: PrEP for injecting drug users","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e1000423","DOI":"10.1371\/journal.pmed.1000423","article-title":"Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: A modeling analysis for Ukraine","volume":"8","author":"SS Alistar","year":"2011","journal-title":"PLoS Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2105\/AJPH.90.7.1100","article-title":"HIV transmission and the cost-effectiveness of methadone maintenance","volume":"90","author":"GS Zaric","year":"2000","journal-title":"Am J Public Health"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1287\/mnsc.46.8.1013.12025","article-title":"Methadone maintenance and HIV prevention: a cost-effectiveness analysis","volume":"46","author":"GS Zaric","year":"2000","journal-title":"Manage Sci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e5945","DOI":"10.1136\/bmj.e5945","article-title":"MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, et al. (29012) Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis","volume":"345","journal-title":"BMJ"},{"key":"ref13","unstructured":"World Health Organization (2013) Data on the HIV\/AIDS response: Antiretroviral therapy coverage by country. Geneva, Switzerland."},{"key":"ref14","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS) (2008) Ukraine - National report on monitoring progress towards the UNGASS declaration of commitment on HIV\/AIDS. Geneva: United Nations."},{"key":"ref15","unstructured":"Ministry of Health of Ukraine (2012) Ukraine Harmonized AIDS Response Progress Report. Kyev, Ukraine: Ministry of Health Ukraine."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1136\/sti.2008.031195","article-title":"The most severe HIV epidemic in Europe: Ukraine\u2019s national HIV prevalence estimates for 2007","volume":"84","author":"YV Kruglov","year":"2008","journal-title":"Sex Transm Infect"},{"key":"ref17","unstructured":"Celentano DD, Beyrer C, Wolfe D, Elovich R, Boltaev A, <etal>et al<\/etal>.. (2008) HIV in Central Asia: Tajikistan, Uzbekistan and Kyrgyzstan. Public Health Aspects of HIV\/AIDS in Low and Middle Income Countries. Springer New York. 557\u2013581."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0140-6736(08)61311-2","article-title":"Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review","volume":"372","author":"BM Mathers","year":"2008","journal-title":"Lancet"},{"key":"ref19","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS) (2008) Ukraine - Country situation fact sheet. Geneva: United Nations."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0376-8716(89)90005-7","article-title":"Methadone-assisted rehabilitation of Swedish heroin addicts","volume":"24","author":"L Gr\u00f6nbladh","year":"1989","journal-title":"Drug and Alcohol Dependence"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1097\/QAD.0b013e328010c7d0","article-title":"Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia","volume":"20","author":"EF Long","year":"2006","journal-title":"AIDS"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/01.olq.0000221335.80508.fa","article-title":"The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine","volume":"33","author":"P Vickerman","year":"2006","journal-title":"Sex Transm Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMsa042657","article-title":"Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy","volume":"352","author":"GD Sanders","year":"2005","journal-title":"N Engl J Med"},{"key":"ref24","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2008) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: United States Department of Health and Human Services."},{"key":"ref25","unstructured":"World Health Organization (WHO) (2006) Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach - 2006 Revision. Geneva: World Health Organization."},{"key":"ref26","unstructured":"World Health Organization (2013) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization, HIV\/AIDS Programme."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies","volume":"360","author":"M Egger","year":"2002","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.7326\/0003-4819-133-6-200009190-00007","article-title":"Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy","volume":"133","author":"S Grabar","year":"2000","journal-title":"Ann Intern Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-139-10-200311180-00008","article-title":"Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350\u00d7109 cells\/L","volume":"139","author":"E Wood","year":"2003","journal-title":"Ann Intern Med"},{"key":"ref30","first-page":"96","article-title":"Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV","volume":"40","author":"J Castilla","year":"2005","journal-title":"J AIDS"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"MS Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"ref32","unstructured":"World Health Organization (WHO) (2003) Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization."},{"key":"ref33","unstructured":"World Health Organization (WHO) (2005) Summary Country Profile for HIV\/AIDS Treatment Scale-Up - Ukraine. Geneva: World Health Organization."},{"key":"ref34","unstructured":"World Health Organization (WHO) (2009) Global Price Reporting Mechanism. Geneva: World Health Organization."},{"key":"ref35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.drugpo.2006.12.011","article-title":"HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine\u2013programme description and policy implications","volume":"18","author":"RD Bruce","year":"2007","journal-title":"Int J Drug Policy"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, <etal>et al<\/etal>.. (2007) Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technology Assessment. Southampton, United Kingdom: National Institute for Health Research - Health Technology Assessment Programme.","DOI":"10.3310\/hta11090"},{"key":"ref37","unstructured":"International HIV\/AIDS Alliance in Ukraine (2008) Methadone substitution therapy starts in Ukraine. Kyiv, Ukraine: International HIV\/AIDS Alliance in Ukraine."},{"key":"ref38","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/QAI.0b013e3181e19a54","article-title":"Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men","volume":"54","author":"SA Golub","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11904-010-0057-1","article-title":"Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation","volume":"7","author":"SA Golub","year":"2010","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/apc.2010.0222","article-title":"Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings","volume":"25","author":"GM Myers","year":"2011","journal-title":"AIDS Patient Care STDS"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-156-8-201204170-00004","article-title":"The cost-effectiveness of preexposure prophylaxis for HIV prevention in men who have sex with men in the United States","volume":"156","author":"JL Juusola","year":"2012","journal-title":"Ann Intern Med"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Gold MR, Siegel J, Russell L, Weinstein M (1996) Cost-Effectiveness in Health and Medicine. New York: Oxford University Press.","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"ref43","unstructured":"UNAIDS\/WHO Working Group on Global HIV\/AIDS and STI Surveillance (2008) Epidemiological Factsheet on HIV and AIDS: Core Data on Epidemiology and Response - Ukraine. Geneva: World Health Organization (WHO) and Joint United Nations Programme on HIV\/AIDS (UNAIDS)."},{"key":"ref44","unstructured":"Murray CJ, Lopez A (2002) World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization."},{"key":"ref45","unstructured":"The World Bank (2013) GDP per capita, PPP (current international $). Washington, DC: World Bank."},{"key":"ref46","unstructured":"Partnership for Supply Chain Management (2013) E-catalog: ARVs."},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e1001401","DOI":"10.1371\/journal.pmed.1001401","article-title":"The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies","volume":"10","author":"GB Gomez","year":"2013","journal-title":"PLoS Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/QAD.0b013e32830e00f5","article-title":"Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness","volume":"22","author":"K Desai","year":"2008","journal-title":"AIDS"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"e1001323","DOI":"10.1371\/journal.pmed.1001323","article-title":"The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study","volume":"9","author":"GB Gomez","year":"2012","journal-title":"PLoS Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1086\/597095","article-title":"HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness","volume":"48","author":"AD Paltiel","year":"2009","journal-title":"Clinical Infectious Diseases"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"e59549","DOI":"10.1371\/journal.pone.0059549","article-title":"Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study","volume":"8","author":"BE Nichols","year":"2013","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/QAD.0b013e32835ca2dd","article-title":"The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis","volume":"27","author":"I Cremin","year":"2013","journal-title":"AIDS"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"e1001123","DOI":"10.1371\/journal.pmed.1001123","article-title":"Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study","volume":"8","author":"TB Hallett","year":"2011","journal-title":"PLoS Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"e13646","DOI":"10.1371\/journal.pone.0013646","article-title":"Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa","volume":"5","author":"C Pretorius","year":"2010","journal-title":"PLoS One"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1477-7517-2-16","article-title":"A situational picture of HIV\/AIDS and injection drug use in Vinnitsya, Ukraine","volume":"2","author":"K Barcal","year":"2005","journal-title":"Harm Reduct J"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/QAD.0b013e328010e019","article-title":"Predictors of HIV sero-status among drug injectors at three Ukraine sites","volume":"20","author":"RE Booth","year":"2006","journal-title":"AIDS"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0376-8716(06)80009-8","article-title":"Predictors of risky needle use following interventions with injection drug users in Ukraine","volume":"82","author":"RE Booth","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Long EF, Stavert RR (2013) Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis. J Gen Intern Med Epub ahead of print.","DOI":"10.1007\/s11606-013-2417-1"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/cid\/cis225","article-title":"The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women","volume":"54","author":"RP Walensky","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0277-9536(96)00258-4","article-title":"Effectiveness of condoms in preventing HIV transmission","volume":"44","author":"SD Pinkerton","year":"1997","journal-title":"Soc Sci Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(10)60832-X","article-title":"Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward","volume":"376","author":"D Wolfe","year":"2010","journal-title":"Lancet"},{"key":"ref62","unstructured":"Dvoriak S (2007) Opioid Substitution Therapy (OST) with Buprenorphine in Ukraine - Way to Prevent HIV\/AIDS among IDUs. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia."}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0086584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T18:55:25Z","timestamp":1716490525000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0086584"}},"subtitle":[],"editor":[{"given":"Yazdan","family":"Yazdanpanah","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,28]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0086584","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,28]]}}}